SAM
BEAM icon

Smartleaf Asset Management’s Beam Therapeutics BEAM Stock Holding History

Smartleaf Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5K Buy
478
+113
+31% +$3.13K ﹤0.01% 2305
2025
Q4 		$10.2K Buy
365
+197
+117% +$5.03K ﹤0.01% 2395
2025
Q3 		$4.02K Buy
168
+13
+8% +$259 ﹤0.01% 2446
2025
Q2 		$2.6K Sell
155
-69
-31% -$1.2K ﹤0.01% 2257
2025
Q1 		$4.97K Sell
224
-122
-35% -$3.2K ﹤0.01% 2188
2024
Q4 		$8.74K Buy
346
+216
+166% +$5.51K ﹤0.01% 2043
2024
Q3 		$3.26K Buy
130
+22
+20% +$568 ﹤0.01% 2305
2024
Q2 		$2.59K Buy
108
+93
+620% +$2.28K ﹤0.01% 2117
2024
Q1 		$509 Buy
+15
New +$467 ﹤0.01% 1738

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Smartleaf Asset Management's BEAM Position: Q1 2026 in Review

Smartleaf Asset Management increased its Beam Therapeutics (BEAM) stake by 31% in Q1 2026, buying an estimated $3.13K and bringing the position to 478 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Smartleaf Asset Management first reported a position in BEAM in Q1 2024 and has held it in 9 quarters since. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • Smartleaf Asset Management held 478 shares of Beam Therapeutics worth $10.5K as of Q1 2026.
  • Smartleaf Asset Management bought 113 Beam Therapeutics shares in Q1 2026, an estimated $3.13K.
  • Beam Therapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2305 holding.
  • Smartleaf Asset Management first reported a position in Beam Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.